Prosecution Insights
Prosecution Insights
12 pending office actions • 8 clients • 12 examiners • 9 art units • 0 of 12 (0%) have an AI response strategy ready • 24 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (50%) |
| §112 only | 1 (8%) |
| No statute on record | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARVICH, MARIA | 1 | 54.7% | +27.4% |
| JUEDES, AMY E | 1 | 44.5% | +41.0% |
| ARNOLD, ERNST V | 1 | 48.0% | +12.9% |
| JOHNSON, TIRONE DEREK | 1 | — | — |
| PENNINGTON, KATIE LEIGH | 1 | 27.3% | +60.6% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 53.2% | +58.5% |
| DONOGHUE, BRITTNEY ERIN | 1 | 59.8% | +55.2% |
| NICKOL, GARY B | 1 | 43.9% | +26.4% |
| SULLIVAN, DENNIS JOHN | 1 | 61.0% | +49.9% |
| IANNUZO, NATALIE NMN | 1 | 12.1% | +80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | IANNUZO, NATALIE NMN | 24d overdue |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | PENNINGTON, KATIE LEIGH | 29d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17978647 | ANTIBIOTIC COMBINATION THERAPIES | ESPINOSA, CLAUDIA EDILMA | 31d overdue |
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | IANNUZO, NATALIE NMN | 24d overdue |
| 19342217 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | MARVICH, MARIA | 16d overdue |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | DONOGHUE, BRITTNEY ERIN | 15d overdue |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NICKOL, GARY B | 15d overdue |
| 17616246 | BREAST CANCER DETECTION METHODS | SULLIVAN, DENNIS JOHN | 5d overdue |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | PENNINGTON, KATIE LEIGH | 29d |
| 18700024 | NANOPARTICULATE FORMULATION | ARNOLD, ERNST V | 46d |
| Client (Assignee) | Pending OAs |
|---|---|
| DYNO THERAPEUTICS, INC. | 2 |
| NEOGAP THERAPEUTICS AB | 2 |
| Regeneron | 2 |
| Bioversys | 2 |
| NewImmune II, LLC | 1 |
| Novartis | 1 |
| CAMBRIDGE ENTERPRISE LIMITED | 1 |
| BP | 1 |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| 1644 | 2 |
| 1675 | 2 |
| 1613 | 1 |
| 1654 | 1 |
| 1643 | 1 |
| 1642 | 1 |
| 1653 | 1 |
| 1637 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19342217 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | Dyno Therapeutics, Inc. | MARVICH, MARIA | 1634 | Other | Non-Final OA | 16d overdue | Pending | Sep 26, 2025 |
| 19317328 | T-CELL EXPANSION METHOD AND USES | Neogap Therapeutics AB | JUEDES, AMY E | 1644 | Other | Non-Final OA | 57d | Pending | Sep 03, 2025 |
| 18700024 | NANOPARTICULATE FORMULATION | Newimmune Ii, LLC | ARNOLD, ERNST V | 1613 | Other | Non-Final OA | 46d | Pending | Apr 10, 2024 |
| 18452452 | INTERFERON RECEPTOR AGONISTS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. | JOHNSON, TIRONE DEREK | 1675 | §103 | Non-Final OA | 34d | Pending | Aug 18, 2023 |
| 18042890 | IMPROVED DEPENDOPARVOVIRUS PRODUCTION COMPOSITIONS AND METHODS | Dyno Therapeutics, Inc. | PENNINGTON, KATIE LEIGH | 1634 | §103 | Non-Final OA | 29d | Pending | Feb 24, 2023 |
| 17978647 | ANTIBIOTIC COMBINATION THERAPIES | BIOVERSYS AG | ESPINOSA, CLAUDIA EDILMA | 1654 | Other | Final Rejection | 31d overdue | Pending | Nov 01, 2022 |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Regeneron Pharmaceuticals, Inc. | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | 15d overdue | Pending | Aug 15, 2022 |
| 17620987 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG | NICKOL, GARY B | 1643 | §112 | Non-Final OA | 15d overdue | Pending | Dec 20, 2021 |
| 17616246 | BREAST CANCER DETECTION METHODS | Cambridge Enterprise Limited | SULLIVAN, DENNIS JOHN | 1642 | §103 | Non-Final OA | 5d overdue | Pending | Dec 03, 2021 |
| 17613898 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | BP CORPORATION NORTH AMERICA INC. | IANNUZO, NATALIE NMN | 1653 | §103 | Non-Final OA | 24d overdue | Pending | Nov 23, 2021 |
| 17417601 | PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER | Neogap Therapeutics AB | JOHANSEN, PETER N. | 1644 | Other | Final Rejection | 17d overdue | Pending | Jun 23, 2021 |
| 17055511 | BACTERIAL VECTORS FOR GENETIC MANIPULATION OF BACTERIA | BIOVERSYS AG | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Non-Final OA | 12d | Pending | Nov 13, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial